Showing results (81-90 of 331) with videos related to
Sort By:
Pageof 34
Cancer Letters|September 26, 2020
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cellsSiyeon Park, Tae Min Kim, Sung-Yup Cho, et al.Leukemia & Lymphoma|November 11, 2014
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisoneBhumsuk Keam, Hyerim Ha, Tae Min Kim, et al.Journal of Neuro-Oncology|December 29, 2025
Documented advance care planning elements and end-of-life care patterns in malignant glioma vs. major solid tumors: a single-center retrospective studyYe Sul Jeung, Wan Taek Lee, Yejin Kim, et al.The Journal of Urology|May 23, 2015
The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell CarcinomaJi-Yeon Kim, Se-Hoon Lee, Kyung Chul Moon, et al.Cancer Research and Treatment|November 20, 2015
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-AnalysisRyul Kim, Seokyung Hahn, Junghoon Shin, et al.Translational Oncology|November 27, 2022
The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell linesJeongjae Lee, Bhumsuk Keam, Soyeon Kim, et al.JAMA|April 10, 2014
Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysisJune-Koo Lee, Seokyung Hahn, Dong-Wan Kim, et al.Oncoimmunology|December 15, 2018
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinomaSeong-Ho Kang, Bhumsuk Keam, Yong-Oon Ahn, et al.Cancer Research and Treatment|April 14, 2015
Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab EraHyerim Ha, Bhumsuk Keam, Tae Min Kim, et al.Cancer Medicine|July 25, 2023
Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinomaDae Ho Lee, Hye Ryun Kim, Bhumsuk Keam, et al.Pageof 34